versus baseline in HF patients (34.4 ± 3.2 to 33.7 ± 3.8 mm Hg and 93.8 ± 2.6 to 94.9 ± 2.6%, respectively) and volunteers (39.5 ± 3.0 to 38.2 ± 3.8 mm Hg and 96.9 ± 1.3 to 97.8 ± 0.9%). While asleep during ASV, PtcCO 2 increased to 36.3 ± 3.8 mm Hg and SaO 2 decreased to 93.8 ± 2.6% in HF patients, with similar changes in volunteers (PtcCO 2 41.7 ± 3.0 mm Hg, SaO 2 97.1 ± 1.2). All comparisons were statistically significant (p ≤ 0.05, except the PtcCO 2 decrease in both groups when awake). Conclusions: ASV therapy might result in hyperventilation when subjects are awake, but while asleep, PtcCO 2 increased to mid-normal values, effects that would be favorable in HF patients with CSR.
Although the pathophysiology of CSR in HF is still not fully understood, pulmonary congestion due to left ventricular dysfunction with increased pulmonary capillary wedge pressure is thought to lead to an activation of pulmonary J receptors. This could promote a greater sensitivity of central CO 2 chemoreceptors and, consequently, an altered apneic threshold with the net effect of an increase in ventilation (hyperventilation) with low-normal to decreased levels of CO 2 [3] .
During sleep and in patients with CSA (in contrast to healthy men), the above-mentioned higher sensitivity towards carbon dioxide pressure (pCO 2 ) explains why they periodically reach the apneic threshold, resulting in repetitive apneas [4] . Thus, in patients with CSR, one or two deep breaths can be enough to cause an apnea [4] .
There is currently no clear consensus on whether CSR in HF patients should be treated because opinion varies as to whether CSR just represents a compensatory physiological mechanism of the failing heart or whether it might be an independent risk factor for death [5, 6] . Therefore, the results of large multicenter, randomized clinical studies investigating the impact of adaptive servoventilation (ASV) therapy on mortality in such patients are awaited with interest [7] .
Nevertheless, the most effective method for treating CSR in HF is ASV or, more recently, enhanced ASV (eASV) [8] [9] [10] [11] . ASV has been shown to be more effective than continuous positive airway pressure (CPAP), bilevel positive airway pressure (BiPAP) therapy or oxygen therapy and to improve cardiac function [8] [9] [10] 12] . With ASV, upper airway patency is ensured by a fixed amount of end-expiratory positive airway pressure (EPAP) or a varied amount of EPAP (known as eASV; accounting for comorbid obstructive events in HF patients with CSR), while a varying amount of inspiratory pressure (inspiratory positive airway pressure, IPAP) supports inspiration with decreasing breathing amplitude or even ensures inspiration with sustained breathing efforts [9] . All available ASV devices indirectly aim to avoid hyperventilation by dynamically decreasing effective minute ventilation to 90% of the patient's ventilation analyzed over a period of the last 3 min. Thus, the net effect is supposed to be a (desired) increase in pCO 2 during the night, which is another feature differentiating ASV from oxygen, CPAP or BiPAP therapies. The ASV device used in this study was one of the latest (enhanced) ASV devices now available, the third-generation PaceWave TM device (ResMed). To the best of our knowledge, it has not yet been shown whether eASV is associated with the desired increase in pCO 2 in HF patients with CSR. Therefore, this study investigated the effects of 60 min of ASV treatment on oxygen saturation (SaO 2 ) and pCO 2 in HF patients with CSR and in healthy volunteers. In addition, we analyzed the influence of sleep on ASV (falling asleep was only allowed during ASV therapy). This observation was intended to verify whether the abovementioned ASV algorithm of a 90% flow-triggered target minute volume can only be administered sufficiently during sleep. It was hypothesized that this (mechanical) control of breathing might only be successful in sleeping patients/volunteers.
Material and Methods

Study Design
A cohort of healthy medical student volunteers and HF patients with CSR were ventilated for 1 h. The effects of ventilation were determined by comparing assessments made 30 min before and after ventilation and without any mask or intervention in place ( fig. 1 ). Both patients and volunteers were asked to stay awake during the 30 min before and after ASV but were asked to fall asleep -if possible -while receiving ASV. The effects of ASV on transcutaneous pCO 2 (PtcCO 2 ) and SaO 2 were first analyzed in all participants, irrespective of any sleeping during ASV, and then in those who actually slept during ASV.
Methods
From July 2012 to January 2013, 20 consecutive patients with stable HF [left ventricular ejection fraction (LVEF) <50%; New York Heart Association class ≥ II] and nocturnal CSR [apnea-hypopnea index (AHI) ≥ 15/h] who were receiving treatment with ASV and 15 healthy, young medical students (LVEF ≥ 60%, AHI <5/h, no history of disease) were enrolled. Echocardiography was performed in all participants to determine LVEF and other cardiac parameters. Additional clinical data (hypercapnic ventilatory response, diffusion capacity and pulmonary function) were obtained from patients before initiation of their ongoing nocturnal ASV treatment.
The study protocol was approved by the local ethics committee, and all patients and volunteers gave written informed consent to participate in the trial. The study was carried out in accordance with the Declaration of Helsinki.
After resting in a supine position for at least 20 min, SaO 2 , PtcCO 2 and wakefulness were continuously monitored for another 30 min before, during 1 h of ASV and 30 min after ASV [PaceWave TM device (ResMed), third-generation (enhanced) ASV device] using polysomnography (PSG; SOMNOscreen TM plus, Somnomedics -SaO 2 and vigilance) and transcutaneous measurement (V-Stats TM 3.00, SenTec AG -pCO 2 ). PSG consisted of a 12-channel EEG and a finger sensor measuring SaO 2 four times each second. PtcCO 2 measurements were taken every 4 s. All investigations were performed in a quiet room, allowing the patients and volunteers to fall asleep during ASV (but not in the 30 min before and after ASV).
With regard to the analysis of pCO 2 levels during sleep, the focus was on identifying periods where sleep was continuous. Therefore, shorter periods of sleep (<3 min) or shorter transitions to sleep were disregarded so that pCO 2 levels could be averaged for stable periods where subjects were definitely asleep or awake.
The following strategy for ASV pressure settings was applied to ensure that both subject groups were exposed to comparable pressure levels: HF patients were ventilated using their median therapeutic pressure levels as a minimum for EPAP and IPAP for this 1 h of ASV (median therapeutic pressure values were taken from a hard copy printout of data from the ASV device they were already being treated with). The volunteers were enrolled into the study after the patients, and the mean values of the median EPAP and IPAP values used in HF patients were used as a minimum.
The DOMINO software (version 2.5.0, Somnomedics) was used to analyze sleep stages, which was performed in accordance with the most recent guidelines of the American Association of Sleep Medicine (AASM) [13] . The AASM guidelines were also applied when analyzing the polygraphic examinations of patients and volunteers that were undertaken to verify sleep-disordered breathing. Both the DOMINO software and the V-Stats TM 3.00 software were used to compare mean values of SaO 2 and PtcCO 2 for the 30 min before, 1 h during and 30 min after ASV (part one of the analysis -overall effects regardless of vigilance during ASV) . Subsequently, both PtcCO 2 and SaO 2 during ASV were analyzed depending on wakefulness in patients and volunteers who fell asleep during ASV (part two of the analysis; 'awake during ASV' vs. 'asleep during ASV').
Statistical Analysis
All analyses were performed using Sigma Plot software (version 11.0, Systat Software Ltd.). Results are expressed as mean ± standard deviation. A one-way repeated measures ANOVA was employed to detect statistically significant overall intraindividual differences in PtcCO 2 and SaO 2 .
A paired t test was used to directly compare differences in Ptc-CO 2 and SaO 2 in the corresponding periods, whereas a t test was employed if different groups of patients or volunteers were compared. The Mann-Whitney rank sum test was used when data did not have a normal distribution. A χ 2 test was used for categorical data. Pearson correlation was employed to correlate the percentage of time spent sleeping during ASV with changes in PtcCO 2 . A p value <0.05 was considered to be statistically significant.
Results
A total of 20 patients and 15 healthy volunteers were enrolled. Detailed demographic and clinical data are summarized in table 1 . 
ASV Settings and Pressure Exposure
Overall Effect of ASV on PtcCO 2 and SaO 2 (Regardless of Sleep during ASV)
As expected, baseline values for PtcCO 2 and SaO 2 were different in HF patients with documented CSA compared with healthy volunteers. PtcCO 2 was 34.0 ± 2.9 mm Hg in HF patients versus 39.3 ± 2.6 mm Hg in volunteers (p < 0.001), and SaO 2 values were 94.2 ± 2.4 and 97.1 ± 1.2%, respectively (p < 0.001). These differences between groups were maintained throughout the study, although relative changes during treatment were in the same direction in both subject groups. Overall, patients tended to have a lower PtcCO 2 than volunteers ( fig. 2 ) .
Overall, without taking into account wakefulness, ASV had no significant effects on PtcCO 2 and SaO 2 . In healthy volunteers, PtcCO 2 was 39.3 ± 2.6 mm Hg before ASV, 37.2 ± 5.2 mm Hg during ASV and 39.1 ± 2.7 mm Hg after ASV. However, SaO 2 improved significantly from 97.1 ± 1.2% before ASV to 97.7 ± 1.0% during ASV (p = 0.004). In patients with HF, PtcCO 2 also remained stable (34.0 ± 2.9 mm Hg before ASV, 33.6 ± 4.3 mm Hg during ASV and 34.1 ± 3.5 mm Hg after ASV), while SaO 2 improved from 94.2 ± 2.4% before ASV to 94.9 ± 2.5% during ASV (p = 0.008). Values are expressed as mean ± standard deviation unless otherwise stated. 6MWD = 6-min walk distance; ACEI = angiotensin-converting enzyme inhibitors; ARB = angiotensin receptor blockers; FEV 1 = forced expiratory volume in 1 s; HCVR = hypercapnic ventilatory response; IVC = inspiratory vital capacity; SD = standard deviation; TLCO = diffusing capacity or transfer factor of the lung for carbon monoxide. It is an important observation that the different effects of ASV therapy in HF patients and healthy volunteers are dependent on wakefulness. As indicated by a decrease in PtcCO 2 and an increase in SaO 2 in both subject groups when awake, ASV was associated with a trend towards a (further) increase in ventilation (hyperventilation). In contrast, while asleep during ASV treatment, PtcCO 2 increased and SaO 2 decreased in both subject groups. During ASV in HF patients, PtcCO 2 was 33.7 ± 3.8 mm Hg while awake versus 36.3 ± 3.8 mm Hg while asleep (p < 0.001); the corresponding values for SaO 2 were 94.9 ± 2.6 and 93.8 ± 2.6%, respectively (p < 0.001).
Effects of ASV on PtcCO 2 and SaO 2 in Dependence of
The findings were similar in healthy volunteers, with a PtcCO 2 of 38.2 ± 3.8 mm Hg while awake during ASV and 41.7 ± 3.0 mm Hg while asleep (p < 0.001), and SaO 2 values of 97.8 ± 0.9 and 97.1 ± 1.2%, respectively (p = 0.003). As can also be seen in figure 2 , the difference in PtcCO 2 also reached statistical significance in both subject groups for the comparison of asleep during ASV and before ASV. However, there were still marked interindividual variations in the change in PtcCO 2 associated with ASV while asleep or awake. These variations were best explained taking into account the precise time slept during ASV in both subject groups.
There was a significant correlation between the percentage of time spent asleep during ASV and changes in PtcCO 2 in both patients (r = 0.622; p = 0.003) and volunteers (r = 0.657; p = 0.008; fig. 3 ).
To further investigate factors associated with hyperventilation during ASV therapy, volunteers were divided into two groups based on the overall change from baseline in PtcCO 2 during ASV. This was intended to extend previous findings by determining whether it was really only being asleep during ASV that accounted for the observed effects on PtcCO 2 . Five volunteers met the definition of hypocapnia (PtcCO 2 ≤ 35 mm Hg) during ASV, and respiratory and sleep stage data of these subjects were compared with those of the remaining 10 volunteers (Ptc-CO 2 >35 mm Hg). A slightly different strategy was used for patients because underlying CSR meant that some were already hypocapnic before ASV. Therefore, 5 patients whose difference between mean PtcCO 2 before and during ASV was ≥ 2 mm Hg were identified ( table 2 ) . Hyperventilation in these patients was clearly evident based on respiratory parameters (i.e. breathing frequency, breathing volume and resulting breathing minute vol- ume, and target minute ventilation) that were all statistically significantly higher than in the other 15 patients (difference in PtcCO 2 before and during ASV <2 mm Hg). This deterioration of hyperventilation in 5 patients was not explained by baseline PtcCO 2 , SaO 2 or any baseline patient characteristics, including PS or EPAP. However, patients with hyperventilation during ASV slept significantly less during ASV than those who did not (11.3 ± 15.7 vs. 44.1 ± 28.5% sleep time during ASV; p = 0.026).
A similar relationship was documented in healthy volunteers. The 5 volunteers with PtcCO 2 ≤ 35 mm Hg slept significantly less during ASV compared with those without hyperventilation (5.0 ± 11.2 vs. 38.3 ± 22.2% sleep time during ASV; p = 0.008). In healthy volunteers, another parameter was also significantly different in those with versus those without hyperventilation: the increase in PS was statistically significantly and clinically relevantly higher (64.3 ± 29.7 vs. 23.3 ± 6.1%; p = 0.012). This resulted in a statistically significantly higher IPAP in hyperventilated (quite awake) volunteers than in nonhyperventilated (quite asleep) volunteers (18.5 ± 1.8 vs. 16.4 ± 0.7 mm Hg; p = 0.031). Thus, in volunteers, both wakefulness and PS might be directly or indirectly responsible for hyperventilation.
Discussion
CSR itself is characterized by hyperventilation with low-normal to depressed pCO 2 , even during daytime while awake [3] . Indeed, in our study, pCO 2 in HF patients with CSR was significantly lower compared to healthy volunteers and during the entire study [14, 15] . ASV indirectly acknowledges this hyperventilation by using algorithms with a target ventilation of only 90% of patients' minute ventilation analyzed over a period of the last 3 min.
However, despite the built-in algorithm, our study even found a tendency for PtcCO 2 to (further) decrease in both awake HF patients with CSR and awake healthy volunteers during 1 h of ASV and as compared to baseline.
There are two mechanisms that could help to understand why ASV was associated with a trend towards hyperventilation in both subject groups while awake during ASV. Firstly, it is generally accepted that positive airway pressure (PAP) devices can lead to hyperinflation (i.e. higher functional residual capacity) of the lungs through PAP [16] . An increase in dead space could have resulted in dyspnea, which in turn causes deeper breaths and increases in IPAP because dyspnea might be misinterpreted as an apnea. Secondly, in healthy volunteers naïve to PAP therapy, ASV might further exaggerate ventilation (induce ventilation instability), leading to false high presettings of the PaceWave TM device with inappropriately high target ventilation. The device would then even 'defend' its target minute ventilation against the subject's drive to breathe less by increasing PS. This would provide further explanation for the observed inappropriate increase in PS in rather hyperventilated (and awake) volunteers during ASV.
In contrast to wakefulness, we observed an appreciable increase in PtcCO 2 and attenuation of hyperventilation during sleep in both HF patients and volunteers when on ASV and compared to PtcCO 2 levels at baseline. More specifically, time spent sleeping during ASV even correlated with the change in PtcCO 2 , highlighting that increases in PtcCO 2 were even more significant the more the subjects slept during ASV. Apparently, the ASV device used in this study probably succeeded at running its algorithm in sleeping subjects, which is in accordance with a previous work [9] .
The different results found for pCO 2 levels in dependency on vigilance during ASV are probably due to ventilatory control being largely dependent on consciousness [17] [18] [19] [20] [21] [22] . During sleep, the control of breathing becomes dependent on chemical and mechanical reflex feedback [17, 22] . The reason for this is loss of the so-called 'wakefulness drive', making it easier for any ventilation to change CO 2 levels in men from early non-REM sleep stages onwards [17] [18] [19] 22] .
The fact that CSR is accompanied by its characteristic hyperventilation (decrease in pCO 2 ) from early sleep stages onwards makes it even more likely that the increase in pCO 2 observed in our sleeping HF patients who are predisposed to CSR during sleep is a result of the treatment of hyperventilation by the built-in algorithm of the ASV device to treat hyperventilation [23, 24] . The relevance of such algorithms favorably altering pCO 2 in patients with CSR is well-underlined by studies demonstrating that even slight increases in pCO 2 of about 2 mm Hg are sufficient to diminish CSR in HF patients [4, 15] .
In contrast to patients with CSR, sensitivity towards pCO 2 and breathing volume decrease during sleep in healthy men, resulting in increases in pCO 2 from early non-REM sleep stages onwards [20, 21] . Thus, the increase in pCO 2 in volunteers during sleep and with ASV might be partly explained by physiological increases in pCO 2 in sleeping healthy men and not necessarily by the ASV algorithm [20, 21] .
This study has a number of limitations. Firstly, we were not able to analyze pCO 2 invasively because the study was conducted in a sleep laboratory. However, the validity of transcutaneous blood gas analysis-derived pCO 2 values has been widely confirmed [25, 26] . Another limitation is the small sample size, which did not allow appropriate multivariate analyses. Despite this, statistically significant differences were found, and reasonable explanations for such differences have been provided.
In addition, any conclusions about the built-in 'Auto EPAP' function in the ASV device used in this study, should be drawn cautiously because it was not really utilized ( table 1 ) . In patients, the slight increase in EPAP seen during 1 h of ASV can probably be explained best by comorbid obstructive apneas requiring EPAP. In volunteers, the marginal increase in EPAP most likely occurred because all volunteers were naïve to any type of PAP device. Some of them may have marginally stopped breathing for a short period, which could have been misinterpreted by the device as an obstructive event necessitating EPAP. Finally, the ASV device software (ResScan Software) did not allow us to analyze respiratory parameters in different periods of ventilation, which is why we compared overall sleep and overall respiratory parameters during the 1 h of ASV.
In conclusion, this study shows that ASV treatment was associated with an increase in ventilation in awake HF patients with CSR and in awake healthy volunteers. In contrast, the desired normalization of respiration (attenuation of hyperventilation as one of the key pathophysiological principles of CSR) with ASV occurred during sleep.
